Ranibizumab - Novartis Ophthalmics

Drug Profile

Ranibizumab - Novartis Ophthalmics

Alternative Names: AMD Fab - Genentech; Anti-VEGF fragment; Lucentis; Rabinismab; RG-3645; rhuFab V2; rhuFab V2 AMD; VEGF antibody fragment

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Developer Genentech; Manhattan Eye, Ear & Throat Hospital; Novartis Ophthalmics; University of Bonn
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Registered Diabetic retinopathy
  • Phase III Retinopathy of prematurity
  • Discontinued Retinal telangiectasis

Most Recent Events

  • 01 Oct 2017 Genentech completes a phase II trial for Diabetic macular oedema in USA (Intravitreous) (NCT02363621)
  • 12 Sep 2017 Novartis completes a phase III trial in Diabetic macular oedema in Turkey (Intravitreous) (NCT02262260)
  • 30 Jun 2017 Novartis completes the phase IIIb OCTAVE trial in Wet age-related macular degeneration in Argentina, Austria, Canada, Colombia, Czech Republic, Finland, France, Germany, Greece, Guatemala, Hungary, Ireland, Italy, Lithuania, Mexico, Netherlands, Panama, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey and United Kingdom (Intravitreous) (NCT01780935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top